NSE - Delayed Quote INR

Cipla Limited (CIPLA.NS)

Get top stock picks

1,385.00 -9.70 (-0.70%)

At close: September 4 at 3:15:02 PM GMT+5:30

Get top stock picks

Loading Chart for CIPLA.NS

Chart Range Bar

Interval:

In partnership with ChartIQ

Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA

Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA

India Pharmaceutical Industry Strategic Landscape Report 2025: Competitive Analysis of Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma, and Biocon

India Pharmaceutical Industry Strategic Landscape Report 2025: Competitive Analysis of Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma, and Biocon

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Pfizer deals extend patent life for a top-selling rare disease drug

Pfizer deals extend patent life for a top-selling rare disease drug

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Cipla USA Strengthens Lung Leadership with Community Wellness Initiatives

Cipla USA Strengthens Lung Leadership with Community Wellness Initiatives

DRREDDY.NS

SUNPHARMA.NS

NATCOPHARM.NS

ZYDUSLIFE.NS

LUPIN.NS

DIVISLAB.NS

DRREDDY.BO

AUROPHARMA.NS

MANKIND.NS

SUNPHARMA.BO

Mobilize your Website

View Site in Mobile | Classic

Share by: